BioCardia, Inc. Common Stock
BCDA Real Time Price USDRecent trades of BCDA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BCDA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
BCDA Revenue by Segment or Geography
New patents grants
-
Patent Title: Method of accessing the left atrium with a multi-directional steerable catheter Jul. 16, 2024
-
Patent Title: Radial and trans-endocardial delivery catheter May. 21, 2024
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Nov. 28, 2023
-
Patent Title: Bone marrow derived neurokinin-1 receptor positive (nk1r+) mesenchymal stem cells for therapeutic applications May. 09, 2023
-
Patent Title: Multi-directional steerable catheter Apr. 04, 2023
-
Patent Title: Target site selection, entry and update with automatic remote image annotation Jun. 14, 2022
-
Patent Title: Multi-directional steerable catheter Oct. 12, 2021
-
Patent Title: Devices and methods for accessing the vasculature of a patient Dec. 29, 2020
-
Patent Title: Radial and trans-endocardial delivery catheter Sep. 22, 2020
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Dec. 31, 2019
-
Patent Title: Radial and trans-endocardial delivery catheter Sep. 11, 2018
-
Patent Title: Method of preparing autologous cells and methods of use for therapy Jul. 31, 2018
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Apr. 17, 2018
-
Patent Title: Steerable endoluminal devices and methods Oct. 03, 2017
-
Patent Title: Method of preparing autologous cells and methods of use for therapy Sep. 05, 2017
-
Patent Title: Treatment for chronic myocardial infarct Dec. 13, 2016
-
Patent Title: Treatment for chronic myocardial infarct Nov. 29, 2016
-
Patent Title: Method of preparing autologous cells and method of use for therapy Apr. 05, 2016
-
Patent Title: Method of accessing a contralateral femoral artery of a patient Jul. 14, 2015
-
Patent Title: Method of accessing a renal artery of a patient May. 05, 2015
-
Patent Title: Method of implanting a pfo occluder in a patient Apr. 28, 2015
-
Patent Title: Method of accessing a carotid artery of a patient Apr. 21, 2015
-
Patent Title: Steerable guide catheters and methods for their use Jan. 27, 2015
-
Patent Title: Implant delivery catheter system and methods for its use Sep. 10, 2013
-
Patent Title: Treatment for chronic myocardial infarction Jul. 30, 2013
-
Patent Title: System for treating the heart with potentially embolic agents through a right heart approach Mar. 05, 2013
-
Patent Title: Drug delivery catheters that attach to tissue and methods for their use Sep. 27, 2011
-
Patent Title: Method of treating coronary arteries with perivascular delivery of therapeutic agents Aug. 16, 2011
-
Patent Title: Catheter systems and methods for placing bi-ventricular pacing leads Nov. 23, 2010
-
Patent Title: Bio-interventional therapeutic treatments for cardiovascular diseases Jun. 15, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to BCDA
Recent picks made for BCDA stock on CNBC
ETFs with the largest estimated holdings in BCDA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BCDA stock a Buy, Sell, or Hold?
- What is the price target for $BCDA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BCDA stock?
- Who owns the most shares of $BCDA stock?
- What funds own $BCDA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BCDA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.